Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Geron's Imetelstat Gets Fast Track Status for Myelofibrosis

Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.

Celgene (CELG) Gains But Lags Market: What You Should Know

Celgene (CELG) closed at $99.30 in the latest trading session, marking a +0.46% move from the prior day.

Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance

Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.

Celgene (CELG) Gains As Market Dips: What You Should Know

In the latest trading session, Celgene (CELG) closed at $99.42, marking a +0.05% move from the previous day.

Ekta Bagri headshot

3 Big Biotech Stocks Worth Adding to Your Portfolio Now

We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.

Acceleron Discontinues Mid-Stage Muscular Dystrophy Study

Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.

Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.

Celgene (CELG) Gains But Lags Market: What You Should Know

In the latest trading session, Celgene (CELG) closed at $98.60, marking a +0.22% move from the previous day.

Karyopharm Signs $150M Royalty Agreement to Support Xpovio

Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.

The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial

The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial

Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study

Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.

Mark Vickery headshot

Top Stock Reports for Celgene, Sinopec & HSBC

Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Sinopec (SNP) and HSBC Holdings (HSBC).

Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study

Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.

J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients

J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.

Celgene (CELG) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Celgene (CELG) closed at $98.41, marking a +0.78% move from the previous day.

FDA Grants Orphan Drug Status to Acceleron's PAH Candidate

The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.

Zacks Premium Research headshot

Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer

The latest EU nod makes Roche's (RHHBY) immuno-oncology drug -- Tecentriq -- the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.

Celgene (CELG) Gains But Lags Market: What You Should Know

Celgene (CELG) closed the most recent trading day at $97.43, moving +0.47% from the previous trading session.

Roche Extends Offer to Acquire Spark Therapeutics Yet Again

Roche's (RHHBY) acquisition of Spark Therapeutics gets delayed once again to allow the FTC more time for review.

Sweta Jaiswal, FRM headshot

Top-Performing Biotech ETFs YTD

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.

5 Cancer-Fighting Stocks to Add to Your Portfolio

Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.

Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Celgene (CELG) closed at $96.80, marking a -0.32% move from the previous day.

Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer

Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.

Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.